Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2019

01-11-2019 | Ulcerative Colitis | Original Article

Increased Transfusion Requirements with Pharmacologic Thromboembolism Prophylaxis During Inflammatory Bowel Disease Exacerbation

Authors: Keith Sultan, Dev Shah, Kush Bhorania, Elinor Zhou, Sundas Khan, Nina Kohn, Michael Qiu, Alex Spyropoulos

Published in: Digestive Diseases and Sciences | Issue 11/2019

Login to get access

Abstract

Background

Inflammatory bowel disease (IBD) exacerbation requiring hospitalization increases the risk of venous thromboembolism (VTE), and current guidelines recommend pharmacologic VTE prophylaxis (PVTEP).

Aims

Bleeding risks with PVTEP in this population are poorly defined, and no study has investigated packed red blood cell (PRBC) transfusion requirements in this population.

Methods

We conducted a chart review of all adult hospitalizations for IBD exacerbation within the Northwell Healthcare system. Patient characteristics recorded included demographics, disease type ulcerative colitis or Crohn’s disease, severe disease defined by inpatient corticosteroid or biologic use, and admission hemoglobin. Inpatient use of PVTEP and anti-platelet therapies were identified. The primary outcome was the occurrence of any packed red blood cell (PRBC) transfusion.

Results

In total, 717 patients met inclusion criteria, accounting for 891 admissions. PVTEP was used during 60.4% of admissions, and 11.1% of patient admissions included a transfusion event. Severe disease patients receiving PVTEP had an 18.6% transfusion risk, versus 11.1% for those not receiving PVTEP, OR 1.82, CI (1.04–3.17). One multivariable analysis transfusion was associated with PVTEP, OR 2.11, 95% CI 1.18, 3.77, p = 0.0120, disease severity OR 3.17, 95% CI 1.81,5.54, p < 0.0001, anti-platelet therapies OR 2.46, 95% CI 1.23–4.90, p = 0.0107, bowel resection OR 3.88, 95% CI 1.97,7.63, p < 0.0001 and decreased admission hemoglobin OR 2.01, 95% CI 1.73–2.32, p < 0.0001, but not disease type ulcerative colitis OR 0.71, 95% CI 0.42–1.20.

Conclusion

PVTEP during IBD exacerbation is associated with increased PRBC transfusions. Our findings do not constitute a contraindication to PVTEP, but may be incorporated into patient counseling during inpatient IBD management.
Literature
1.
go back to reference Bernstein CN, Nabalamba A. Hospitalization-based major co morbidity of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol. 2007;21:507–511. Bernstein CN, Nabalamba A. Hospitalization-based major co morbidity of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol. 2007;21:507–511.
3.
go back to reference Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375:657–663.CrossRef Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375:657–663.CrossRef
12.
go back to reference Razik R, Bernstein CN, Sam J, Thanabalan R, Nguyen GC. Survey of perceptions and practices among Canadian gastroenterologists regarding the prevention of venous thromboembolism for hospitalized inflammatory bowel disease patients. Can J Gastroenterol. 2012;26:795–798.CrossRef Razik R, Bernstein CN, Sam J, Thanabalan R, Nguyen GC. Survey of perceptions and practices among Canadian gastroenterologists regarding the prevention of venous thromboembolism for hospitalized inflammatory bowel disease patients. Can J Gastroenterol. 2012;26:795–798.CrossRef
15.
go back to reference Chande N, MacDonald JK, Wang JJ, McDonald JWD. Unfractionated or low molecular weight heparin for induction of remission in ulcerative colitis: a Cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials. Inflamm Bowel Dis. 2011;17:1979–1986. https://doi.org/10.1002/ibd.21776.CrossRefPubMed Chande N, MacDonald JK, Wang JJ, McDonald JWD. Unfractionated or low molecular weight heparin for induction of remission in ulcerative colitis: a Cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials. Inflamm Bowel Dis. 2011;17:1979–1986. https://​doi.​org/​10.​1002/​ibd.​21776.CrossRefPubMed
18.
go back to reference Schulman, S., Kearon, C., & Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–694. https://doi.org/10.1111/j.1538-7836.2005.01204.x.CrossRef Schulman, S., Kearon, C., & Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692–694. https://​doi.​org/​10.​1111/​j.​1538-7836.​2005.​01204.​x.CrossRef
Metadata
Title
Increased Transfusion Requirements with Pharmacologic Thromboembolism Prophylaxis During Inflammatory Bowel Disease Exacerbation
Authors
Keith Sultan
Dev Shah
Kush Bhorania
Elinor Zhou
Sundas Khan
Nina Kohn
Michael Qiu
Alex Spyropoulos
Publication date
01-11-2019
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2019
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05650-2

Other articles of this Issue 11/2019

Digestive Diseases and Sciences 11/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.